BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 139] [Article Influence: 36.2] [Reference Citation Analysis]
Number Citing Articles
1 Kishino K, Enomoto H, Shimono Y, Moriwaki EI, Nishikawa H, Nishimura T, Iwata Y, Iijima H, Nishiguchi S. Association of an Overhydrated State With the Liver Fibrosis and Prognosis of Cirrhotic Patients. In Vivo 2020;34:1347-53. [PMID: 32354929 DOI: 10.21873/invivo.11912] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Li D, Zhu M, Zhou C, Liu X. Effect of Liuweiwuling tablet on biochemical and virological parameters, and quality of life in patients with hepatitis B virus-related cirrhosis: A protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e22065. [PMID: 32925741 DOI: 10.1097/MD.0000000000022065] [Reference Citation Analysis]
3 Kanayama K, Chiba T, Kobayashi K, Koroki K, Maruta S, Kanzaki H, Kusakabe Y, Saito T, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Ooka Y, Nakamoto S, Yasui S, Kanda T, Maruyama H, Kato J, Kato N. Long-term administration of Tolvaptan to patients with decompensated cirrhosis. Int J Med Sci 2020;17:874-80. [PMID: 32308540 DOI: 10.7150/ijms.41454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. The Relationship between Controlling Nutritional (CONUT) Score and Clinical Markers among Adults with Hepatitis C Virus Related Liver Cirrhosis. Nutrients 2018;10:E1185. [PMID: 30158477 DOI: 10.3390/nu10091185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
5 Fried DE, Watson RE, Robson SC, Gulbransen BD. Ammonia modifies enteric neuromuscular transmission through glial γ-aminobutyric acid signaling. Am J Physiol Gastrointest Liver Physiol 2017;313:G570-80. [PMID: 28838986 DOI: 10.1152/ajpgi.00154.2017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
6 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Health-Related Quality of Life in Chronic Liver Diseases: A Strong Impact of Hand Grip Strength. J Clin Med 2018;7:E553. [PMID: 30558298 DOI: 10.3390/jcm7120553] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
7 Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, Torii N, Hashimoto E, Tokushige K. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Intern Med 2017;56:2993-3001. [PMID: 28943585 DOI: 10.2169/internalmedicine.9033-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
8 Hanai T, Shiraki M, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex-stratified analysis. Hepatol Res 2019;49:1414-26. [PMID: 31408558 DOI: 10.1111/hepr.13420] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
9 Yu Z, Li Q, Wang Y, Li P. A potent protective effect of baicalein on liver injury by regulating mitochondria-related apoptosis. Apoptosis 2020;25:412-25. [PMID: 32409930 DOI: 10.1007/s10495-020-01608-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
10 Zhang J, Chen Y, Lin J, Jia R, An T, Dong T, Zhang Y, Yang X. Cyclovirobuxine D Exerts Anticancer Effects by Suppressing the EGFR-FAK-AKT/ERK1/2-Slug Signaling Pathway in Human Hepatocellular Carcinoma. DNA Cell Biol 2020;39:355-67. [PMID: 31913706 DOI: 10.1089/dna.2019.4990] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis. J Gastroenterol Hepatol 2019;34:1809-16. [PMID: 30779213 DOI: 10.1111/jgh.14635] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Deng H, Zheng X, Zha P, Liang H, Huang K, Peng L. Can we perform esophagectomy for esophageal cancer patients with concomitant liver cirrhosis? A comprehensive systematic review and meta-analysis. Diseases of the Esophagus 2019;32:doz003. [DOI: 10.1093/dote/doz003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Conzen KD, Pomfret EA. Liver transplant in patients with portal vein thrombosis: Medical and surgical requirements: Conzen and Pomfret. Liver Transpl 2017;23:S59-63. [DOI: 10.1002/lt.24856] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
14 Chinese Society of Hepatology, Chinese Medical Association. Xu X, Duan Z, Ding H, Li W, Jia J, Wei L, Linghu E, Zhuang H. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatol Int. 2019;13:1-21. [PMID: 30656520 DOI: 10.1007/s12072-018-09923-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
15 Hu X, Shang G, Zhang J, Chen Z, Fu L, Li J, Lu X. Clinical Yi-guan decoction for liver cirrhosis: A protocol for systematic review and meta analysis. Medicine (Baltimore) 2021;100:e24530. [PMID: 33787570 DOI: 10.1097/MD.0000000000024530] [Reference Citation Analysis]
16 Zhang X, Wang D, Chen Z, Guo N, Wang W, Xiong C, Liu J, Yue Y, Sun M. Red cell distribution width-to-lymphocyte ratio: A novel predictor for HBV-related liver cirrhosis. Medicine (Baltimore) 2020;99:e20638. [PMID: 32502047 DOI: 10.1097/MD.0000000000020600] [Reference Citation Analysis]
17 Tsuchihashi J, Koya S, Hirota K, Koga N, Narao H, Tomita M, Kawaguchi T, Hashida R, Nakano D, Tsutsumi T, Yoshio S, Matsuse H, Sanada T, Notsumata K, Torimura T. Effects of In-Hospital Exercise on Frailty in Patients with Hepatocellular Carcinoma. Cancers (Basel) 2021;13:E194. [PMID: 33430438 DOI: 10.3390/cancers13020194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Serum Zinc Concentration and Sarcopenia: A Close Linkage in Chronic Liver Diseases. J Clin Med 2019;8:E336. [PMID: 30862022 DOI: 10.3390/jcm8030336] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
19 Sakaida I, Terai S, Kurosaki M, Okada M, Hirano T, Fukuta Y. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study). J Gastroenterol 2020;55:800-10. [PMID: 32388692 DOI: 10.1007/s00535-020-01691-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
20 Sano A, Kakazu E, Morosawa T, Inoue J, Kogure T, Ninomiya M, Iwata T, Umetsu T, Nakamura T, Takai S, Shimosegawa T. The profiling of plasma free amino acids and the relationship between serum albumin and plasma-branched chain amino acids in chronic liver disease: a single-center retrospective study. J Gastroenterol 2018;53:978-88. [PMID: 29380062 DOI: 10.1007/s00535-018-1435-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
21 Ueno M, Kayahara T, Sunami T, Takayama H, Takabatake H, Morimoto Y, Yamamoto H, Mizuno M. Universal antibiotic prophylaxis may no longer be necessary for patients with acute variceal bleeding: A retrospective observational study. Medicine (Baltimore) 2020;99:e19981. [PMID: 32443300 DOI: 10.1097/MD.0000000000019981] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Theodoridis X, Grammatikopoulou MG, Petalidou A, Kontonika S, Potamianos SP, Bogdanos DP. A Systematic Review of Medical Nutrition Therapy Guidelines for Liver Cirrhosis: Do We Agree? Nutrition in Clinical Practice 2020;35:98-107. [DOI: 10.1002/ncp.10393] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
23 Haraguchi M, Ichinose K, Miyaaki H, Hanada M, Fukushima M, Sasaki R, Miuma S, Hara T, Kugiyama T, Soyama A, Hidaka M, Tsuji A, Yano R, Sekino M, Takahata H, Eguchi S, Nakao K. Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial. Trials 2021;22:137. [PMID: 33579345 DOI: 10.1186/s13063-021-05086-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Calf Circumference as a Useful Predictor of Sarcopenia in Patients With Liver Diseases. In Vivo. 2020;34:2561-2569. [PMID: 32871785 DOI: 10.21873/invivo.12073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis. Hepatol Res 2019;49:82-95. [PMID: 30156741 DOI: 10.1111/hepr.13244] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
26 Haraguchi M, Miyaaki H, Nakamura Y, Narita S, Matsumoto K, Fukushima M, Sasaki R, Miuma S, Takahata H, Yamaguchi N, Nakao K. Assessment of the association between dysphagia and sarcopenia among elderly patients with cirrhosis: Usefulness of the finger-ring test. Arch Gerontol Geriatr 2021;95:104430. [PMID: 34004488 DOI: 10.1016/j.archger.2021.104430] [Reference Citation Analysis]
27 Qin LF, Qin JM, Zhang JQ, Lv XP, Huang LY, Wang JJ. CXCL12 and CXCR4 polymorphisms and expressions in peripheral blood from patients of hepatocellular carcinoma. Future Oncol. 2018;14:1261-1271. [PMID: 29741398 DOI: 10.2217/fon-2017-0613] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
28 Wang L, Wang R, Zhang C, Yue Z, Zhao H, Fan Z, Wu Y, Zhang Y, Liu F, Dong J. Hepatic parenchyma and vascular blood flow changes after TIPS with spectral CT iodine density in HBV-related liver cirrhosis. Sci Rep 2021;11:10535. [PMID: 34006977 DOI: 10.1038/s41598-021-89764-6] [Reference Citation Analysis]
29 Zhang J, Zhang Z, Shi T. Single-center analysis of the inappropriate use of human albumin and nutritional support in hospitalized patients with hypoproteinemia in China. J Int Med Res 2021;49:300060520987731. [PMID: 33750235 DOI: 10.1177/0300060520987731] [Reference Citation Analysis]
30 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
31 Gimm G, Chang Y, Kim HC, Shin A, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Balloon-Occluded Retrograde Transvenous Obliteration versus Transjugular Intrahepatic Portosystemic Shunt for the Management of Gastric Variceal Bleeding. Gut Liver 2018;12:704-13. [PMID: 29938456 DOI: 10.5009/gnl17515] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 8.5] [Reference Citation Analysis]
32 Nishikawa H, Yoh K, Enomoto H, Ikeda N, Aizawa N, Koriyama T, Nishimura T, Nishiguchi S, Iijima H. Anthropometric Measurements and Frailty in Patients with Liver Diseases. Diagnostics (Basel). 2020;10:433. [PMID: 32630551 DOI: 10.3390/diagnostics10060433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
33 Zhou GP, Sun LY, Wei L, Qu W, Zeng ZG, Liu Y, Jiang YZ, Zhu ZJ. Comparision between portosystemic shunts and endoscopic therapy for prevention of variceal re-bleeding: a systematic review and meta-analysis. Chin Med J (Engl) 2019;132:1087-99. [PMID: 30913064 DOI: 10.1097/CM9.0000000000000212] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
34 Nishikawa H, Yuri Y, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Effect of psoas muscle mass after endoscopic therapy for patients with esophageal varices. Medicine (Baltimore) 2017;96:e6868. [PMID: 28489785 DOI: 10.1097/MD.0000000000006868] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
35 Li FC, Fan YC, Li YK, Wang K. Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis. Virol J 2019;16:115. [PMID: 31533748 DOI: 10.1186/s12985-019-1219-4] [Reference Citation Analysis]
36 Catanzaro R, Sciuto M, Lanzafame C, Balakrishnan B, Marotta F. Platelet to lymphocyte ratio as a predictive biomarker of liver fibrosis (on elastography) in patients with hepatitis C virus (HCV)-related liver disease. Indian J Gastroenterol 2020;39:253-60. [PMID: 32833144 DOI: 10.1007/s12664-020-01038-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Adachi T, Takeuchi Y, Takaki A, Oyama A, Wada N, Onishi H, Shiraha H, Okada H. Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. Int J Mol Sci 2021;22:5582. [PMID: 34070416 DOI: 10.3390/ijms22115582] [Reference Citation Analysis]
38 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Factors Associated With Longitudinal QOL Change in Patients With Chronic Liver Diseases. In Vivo 2021;35:2451-6. [PMID: 34182530 DOI: 10.21873/invivo.12524] [Reference Citation Analysis]
39 Kotoh Y, Saeki I, Yamasaki T, Sasaki R, Tanabe N, Oono T, Maeda M, Hidaka I, Ishikawa T, Takami T, Sakaida I. Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma. Clin Nutr 2021;40:3585-91. [PMID: 33386180 DOI: 10.1016/j.clnu.2020.12.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Yada T, Inada Y, Sakamoto H, Higashi H, Kubozono O, Maenohara S, Ido A. Effect of tolvaptan on the prognosis of patients with hepatic ascites. Hepatol Res 2019;49:765-77. [PMID: 30916842 DOI: 10.1111/hepr.13337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
41 Namba M, Hiramatsu A, Aikata H, Kodama K, Uchikawa S, Ohya K, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Tsuge M, Imamura M, Chayama K. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. J Gastroenterol 2020;55:217-26. [PMID: 31485782 DOI: 10.1007/s00535-019-01623-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
42 Hiramine Y, Uto H, Mawatari S, Kanmura S, Imamura Y, Hiwaki T, Saishoji A, Oku M, Tokushige K, Maenohara S, Ido A. Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. J Gastroenterol 2021;56:54-66. [PMID: 32959093 DOI: 10.1007/s00535-020-01727-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ishigami M, Honda T, Kuzuya T, Ishizu Y, Ito T, Kamei H, Ogura Y, Fujishiro M. Revisiting the indications for liver transplantation in cirrhotic patients considering the long‐term outcomes of cirrhotic patients. J Hepatobiliary Pancreat Sci 2020;27:655-62. [DOI: 10.1002/jhbp.777] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Wang JC, Fu R, Tao XW, Mao YF, Wang F, Zhang ZC, Yu WW, Chen J, He J, Sun BC. A radiomics-based model on non-contrast CT for predicting cirrhosis: make the most of image data.Biomark Res. 2020;8:47. [PMID: 32963787 DOI: 10.1186/s40364-020-00219-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zeng X, Sheng X, Wang PQ, Xin HG, Guo YB, Lin Y, Zhong JW, He CZ, Yin J, Liu TT, Ma WJ, Xiao X, Shi PM, Yuan ZL, Yang L, Ma X, Xu JM, Shen XZ, Yang CQ, Zhu X, Lv NH, Xie WF. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatol Int 2021;15:155-65. [PMID: 33385299 DOI: 10.1007/s12072-020-10117-y] [Reference Citation Analysis]
46 Iida A, Kuranuki S, Yamamoto R, Uchida M, Ohta M, Ichimura M, Tsuneyama K, Masaki T, Seike M, Nakamura T. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. Exp Anim 2019;68:417-28. [PMID: 31155606 DOI: 10.1538/expanim.18-0152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yatsuhashi H, Sano H, Hirano T, Shibasaki Y. Real-world hospital mortality of liver cirrhosis inpatients in Japan: a large-scale cohort study using a medical claims database: Prognosis of liver cirrhosis. Hepatol Res 2021;51:682-93. [PMID: 33710718 DOI: 10.1111/hepr.13635] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
48 Wang X, Chen HZ, Liu WT, Liu M, Zhou DQ, Chen Q, Peng B. The association of plasma high-density lipoprotein cholesterol levels and cirrhosis development in obese patients with chronic hepatitis B: a cohort study. Eur J Gastroenterol Hepatol 2021;33:738-44. [PMID: 33079778 DOI: 10.1097/MEG.0000000000001965] [Reference Citation Analysis]
49 Chang J, Dumitrache A, Böhling N, Abu-Omar J, Meyer C, Strobel D, Luetkens J, Luu AM, Rockstroh J, Strassburg CP, Trebicka J, Gonzalez-Carmona MA, Marinova M, Praktiknjo M. Alteration of contrast enhanced ultrasound (CEUS) of hepatocellular carcinoma in patients with cirrhosis and transjugular intrahepatic portosystemic shunt (TIPS). Sci Rep 2020;10:20682. [PMID: 33244180 DOI: 10.1038/s41598-020-77801-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Sarcopenia and Frailty in Chronic Liver Damage: Common and Different Points. In Vivo 2020;34:2549-59. [PMID: 32871784 DOI: 10.21873/invivo.12072] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Nishikawa H, Yoh K, Enomoto H, Ishii N, Iwata Y, Nakano C, Takata R, Nishimura T, Aizawa N, Sakai Y, Ikeda N, Hasegawa K, Takashima T, Iijima H, Nishiguchi S. Extracellular Water to Total Body Water Ratio in Viral Liver Diseases: A Study Using Bioimpedance Analysis. Nutrients 2018;10:E1072. [PMID: 30103528 DOI: 10.3390/nu10081072] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
52 Hashida R, Kawaguchi T, Koya S, Hirota K, Goshima N, Yoshiyama T, Otsuka T, Bekki M, Iwanaga S, Nakano D, Niizeki T, Matsuse H, Kawaguchi A, Shiba N, Torimura T. Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. Oncol Lett 2020;19:2355-67. [PMID: 32194735 DOI: 10.3892/ol.2020.11345] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
53 Hoshi H, Chu PS, Yoshida A, Taniki N, Morikawa R, Yamataka K, Noguchi F, Kasuga R, Tabuchi T, Ebinuma H, Saito H, Kanai T, Nakamoto N. Vulnerability to recurrent episodes of acute decompensation/acute-on-chronic liver failure characterizes those triggered by indeterminate precipitants in patients with liver cirrhosis. PLoS One 2021;16:e0250062. [PMID: 33848309 DOI: 10.1371/journal.pone.0250062] [Reference Citation Analysis]
54 Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis. J Cachexia Sarcopenia Muscle 2017;8:915-25. [PMID: 28627027 DOI: 10.1002/jcsm.12212] [Cited by in Crossref: 79] [Cited by in F6Publishing: 67] [Article Influence: 19.8] [Reference Citation Analysis]
55 Grzych G, Vonghia L, Bout MA, Weyler J, Verrijken A, Dirinck E, Chevalier Curt MJ, Van Gaal L, Paumelle R, Francque S, Tailleux A, Haas JT, Staels B. Plasma BCAA Changes in Patients With NAFLD Are Sex Dependent. J Clin Endocrinol Metab 2020;105:dgaa175. [PMID: 32271385 DOI: 10.1210/clinem/dgaa175] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
56 Toyoda J, Morioka D, Horii N, Nakayama G, Oyama N, Asano F, Izumisawa Y, Miura M, Sato Y, Endo I. Treatment of acute exacerbation of liver-cirrhosis-associated portal vein thrombosis with direct-acting oral anticoagulant, edoxaban, used as an initial treatment in the early postoperative period after abdominal surgery: a case report. J Med Case Rep 2021;15:52. [PMID: 33563326 DOI: 10.1186/s13256-020-02651-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
57 Hara T, Ohara T, Taniguchi M, Sakai H, Oka K, Iwai N, Tsuji T, Okuda T, Nagata A, Komaki T, Sakagami J, Kagawa K. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection. Intern Med 2021;60:2437-43. [PMID: 33612683 DOI: 10.2169/internalmedicine.6664-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Lin M, Zhang F, Wang Y, Zhang B, Zhang W, Zou X, Zhang M, Zhuge Y. Liver cirrhosis caused by chronic Budd-Chiari syndrome. Medicine (Baltimore) 2017;96:e7425. [PMID: 28834866 DOI: 10.1097/MD.0000000000007425] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
59 Zhang K, Zhang Y, Li N, Xing F, Zhao J, Yang T, Liu C, Feng N. An herbal-compound-based combination therapy that relieves cirrhotic ascites by affecting the L-arginine/nitric oxide pathway: A metabolomics-based systematic study. J Ethnopharmacol 2019;241:112034. [PMID: 31226385 DOI: 10.1016/j.jep.2019.112034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
60 Schuster K, Davis K, Hernandez M, Holena D, Salim A, Crandall M. American Association for the Surgery of Trauma emergency general surgery guidelines gap analysis. J Trauma Acute Care Surg 2019;86:909-15. [PMID: 30768554 DOI: 10.1097/TA.0000000000002226] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
61 Xiao W, Huang X, Wang JH, Lin DR, Zhu Y, Chen C, Yang YH, Xiao J, Zhao LQ, Li JO, Cheung CY, Mise Y, Guo ZY, Du YF, Chen BB, Hu JX, Zhang K, Lin XS, Wen W, Liu YZ, Chen WR, Zhong YS, Lin HT. Screening and identifying hepatobiliary diseases through deep learning using ocular images: a prospective, multicentre study. Lancet Digit Health 2021;3:e88-97. [PMID: 33509389 DOI: 10.1016/S2589-7500(20)30288-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Serum Zinc Level Grading System: A Useful Model for Composite Hepatic Events in Hepatitis C Virus-Associated Liver Cirrhosis. J Clin Med 2020;9:E643. [PMID: 32121095 DOI: 10.3390/jcm9030643] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Zhang W, Chen Q, Ye Y, Zou B, Liu Y, Cheng L, Yu J, Zheng S. AntagomiR-199a Enhances the Liver Protective Effect of Hypoxia-Preconditioned BM-MSCs in a Rat Model of Reduced-Size Liver Transplantation. Transplantation 2020;104:61-71. [PMID: 31449185 DOI: 10.1097/TP.0000000000002928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhou H, Long J, Hu H, Tian CY, Lin SD. Liver stiffness and serum markers for excluding high-risk varices in patients who do not meet Baveno VI criteria. World J Gastroenterol. 2019;25:5323-5333. [PMID: 31558876 DOI: 10.3748/wjg.v25.i35.5323] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
65 Cho HJ, Eun JW, Baek GO, Seo CW, Ahn HR, Kim SS, Cho SW, Cheong JY. Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma. J Clin Med 2020;9:E281. [PMID: 31968558 DOI: 10.3390/jcm9010281] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 25.0] [Reference Citation Analysis]
66 Uojima H, Hidaka H, Nakayama T, Sung JH, Ichita C, Tokoro S, Masuda S, Sasaki A, Koizumi K, Egashira H, Kako M. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World J Gastroenterol 2017;23:8062-72. [PMID: 29259382 DOI: 10.3748/wjg.v23.i45.8062] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
67 Wang JW, Qian Y, Wu CS, Zhao NH, Fang Y, Yuan XD, Gao S, Fan YC, Wang K. Combined use of murine double minute-2 promoter methylation and serum AFP improves diagnostic efficiency in hepatitis B virus-related hepatocellular carcinoma. Int J Med Sci 2020;17:3190-9. [PMID: 33173438 DOI: 10.7150/ijms.47003] [Reference Citation Analysis]
68 Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Comparison of Prognostic Impact between the Child-Pugh Score and Skeletal Muscle Mass for Patients with Liver Cirrhosis. Nutrients 2017;9:E595. [PMID: 28604642 DOI: 10.3390/nu9060595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
69 Zhou H, Hu H, Tian M, Chu J, Tian C, Yang Y, Lin S. Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices. Gastroenterol Res Pract 2020;2020:4217512. [PMID: 33376483 DOI: 10.1155/2020/4217512] [Reference Citation Analysis]
70 Zhu Y, Xu W, Hu W, Wang F, Zhou Y, Xu J, Gong W. Discovery and validation of novel protein markers in mucosa of portal hypertensive gastropathy. BMC Gastroenterol 2021;21:214. [PMID: 33971821 DOI: 10.1186/s12876-021-01787-5] [Reference Citation Analysis]
71 Elkilany A, Fehrenbach U, Auer TA, Müller T, Schöning W, Hamm B, Geisel D. A radiomics-based model to classify the etiology of liver cirrhosis using gadoxetic acid-enhanced MRI. Sci Rep 2021;11:10778. [PMID: 34031487 DOI: 10.1038/s41598-021-90257-9] [Reference Citation Analysis]
72 Hiraoka A, Yoshiji H, Iwasa M, Nakanishi H, Karino Y, Nakajima T, Miyaaki H, Shiraki M, Kawaguchi T, Sawada Y, Michitaka K, Okita K. Clinical features of liver cirrhosis patients with muscle cramping: a multicenter study. European Journal of Gastroenterology & Hepatology 2019;31:1557-62. [DOI: 10.1097/meg.0000000000001473] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
73 Nishikawa H, Enomoto H, Iwata Y, Nishimura T, Iijima H, Nishiguchi S. Clinical utility of bioimpedance analysis in liver cirrhosis. J Hepatobiliary Pancreat Sci 2017;24:409-16. [PMID: 28371518 DOI: 10.1002/jhbp.455] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
74 Liu H, Zhu P, Nie C, Ye Q, Gao Y, Liu H, Pang G, Han T. The value of ascitic neutrophil gelatinase-associated lipocalin in decompensated liver cirrhosis with spontaneous bacterial peritonitis. J Clin Lab Anal 2020;34:e23247. [PMID: 32100329 DOI: 10.1002/jcla.23247] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Nishikawa H, Yoh K, Enomoto H, Ikeda N, Takashima T, Aizawa N, Nishimura T, Nishiguchi S, Iijima H. Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases. In Vivo 2021;35:363-71. [PMID: 33402485 DOI: 10.21873/invivo.12267] [Reference Citation Analysis]
76 Takaya H, Namisaki T, Sato S, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Sawada Y, Shimozato N, Kawaratani H, Moriya K, Akahane T, Mitoro A, Yoshiji H. Increased Endotoxin Activity Is Associated with the Risk of Developing Acute-on-Chronic Liver Failure. J Clin Med. 2020;9. [PMID: 32422875 DOI: 10.3390/jcm9051467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Yoh K, Nishikawa H, Enomoto H, Iwata Y, Ikeda N, Aizawa N, Nishimura T, Iijima H, Nishiguchi S. Grip Strength: A Useful Marker for Composite Hepatic Events in Patients with Chronic Liver Diseases. Diagnostics (Basel) 2020;10:E238. [PMID: 32325995 DOI: 10.3390/diagnostics10040238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
78 Chen P, Wang YY, Chen C, Guan J, Zhu HH, Chen Z. The immunological roles in acute-on-chronic liver failure: An update. Hepatobiliary Pancreat Dis Int 2019;18:403-11. [PMID: 31303562 DOI: 10.1016/j.hbpd.2019.07.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
79 Nishina T, Hoshikawa KT, Ueno Y. Current Cell-Based Therapies in the Chronic Liver Diseases. Adv Exp Med Biol 2018;1103:243-53. [PMID: 30484233 DOI: 10.1007/978-4-431-56847-6_13] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
80 Zhang Y, Huang C, Nie Y, Liu Q, Xiao N, Liu L, Zhu X. Soluble CD163 Is a Predictor of Mortality in Patients With Decompensated Cirrhosis. Front Med (Lausanne) 2021;8:698502. [PMID: 34336902 DOI: 10.3389/fmed.2021.698502] [Reference Citation Analysis]
81 Kogiso T, Sagawa T, Kodama K, Taniai M, Tokushige K. Impact of continued administration of tolvaptan on cirrhotic patients with ascites. BMC Pharmacol Toxicol 2018;19:87. [PMID: 30563565 DOI: 10.1186/s40360-018-0277-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Atsukawa M, Tsubota A, Takaguchi K, Toyoda H, Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema. J Gastroenterol Hepatol 2020;35:1229-37. [PMID: 31881554 DOI: 10.1111/jgh.14965] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
83 Shiba S, Chu PS, Nakamoto N, Yamataka K, Taniki N, Ojiro K, Yamaguchi A, Morikawa R, Yoshida A, Ikura A, Ebinuma H, Saito H, Kanai T. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study. BMC Gastroenterol 2020;20:53. [PMID: 32138675 DOI: 10.1186/s12876-020-01205-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Qin L, Qin J, Lv X, Yin C, Zhang Q, Zhang J. MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma. Oncol Lett 2021;22:549. [PMID: 34093770 DOI: 10.3892/ol.2021.12810] [Reference Citation Analysis]
85 Younossi Z, Stepanova M, Omata M, Mizokami M, Walters M, Hunt S. Health utilities using SF-6D scores in Japanese patients with chronic hepatitis C treated with sofosbuvir-based regimens in clinical trials. Health Qual Life Outcomes 2017;15:25. [PMID: 28143559 DOI: 10.1186/s12955-017-0598-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
86 Yuri Y, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Hasegawa K, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Takata R, Iijima H, Nishiguchi S. Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. J Cancer 2017;8:1507-16. [PMID: 28775769 DOI: 10.7150/jca.19175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
87 Tang J, Wang Y, Han T, Mao Q, Cheng J, Ding H, Shang J, Zhang Q, Niu J, Ji F, Chen C, Jia J, Jiang X, Lv N, Gao Y, Wang Z, Wei Z, Chen Y, Zeng M, Mao Y. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterol 2020;20:391. [PMID: 33213378 DOI: 10.1186/s12876-020-01536-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Moriwaki EI, Enomoto H, Saito M, Hara N, Nishikawa H, Nishimura T, Iwata Y, Iijima H, Nishiguchi S. The Anthropometric Assessment With the Bioimpedance Method Is Associated With the Prognosis of Cirrhotic Patients. In Vivo. 2020;34:687-693. [PMID: 32111771 DOI: 10.21873/invivo.11825] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
89 Hasegawa K, Takata R, Nishikawa H, Enomoto H, Ishii A, Iwata Y, Miyamoto Y, Ishii N, Yuri Y, Nakano C, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Impact of Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein in Patients with Hepatitis C Virus-Related Compensated Liver Cirrhosis. Int J Mol Sci. 2016;17. [PMID: 27626413 DOI: 10.3390/ijms17091500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
90 Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H. Management of refractory cirrhotic ascites: challenges and solutions. Hepat Med. 2018;10:55-71. [PMID: 30013405 DOI: 10.2147/hmer.s136578] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
91 Yuan L, Zeng BM, Liu LL, Ren Y, Yang YQ, Chu J, Li Y, Yang FW, He YH, Lin SD. Risk factors for progression to acute-on-chronic liver failure during severe acute exacerbation of chronic hepatitis B virus infection. World J Gastroenterol 2019;25:2327-37. [PMID: 31148904 DOI: 10.3748/wjg.v25.i19.2327] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
92 Zhu Y, Liu C, Chen X, Lu S, Chen J. Hepatoprotective effects and mechanisms of Ixeris denticulate water extract on liver cirrhosis in experimental rat. BMC Complement Med Ther 2020;20:175. [PMID: 32503634 DOI: 10.1186/s12906-020-02957-w] [Reference Citation Analysis]
93 Qi X, Wang J, Li X, Wang Z, Liu Y, Yang H, Li X, Shi J, Xiang H, Liu T, Kawada N, Maruyama H, Jiang Z, Wang F, Takehara T, Rockey DC, Sarin SK; COVID-Cirrhosis-CHESS Group. Clinical course of COVID-19 in patients with pre-existing decompensated cirrhosis: initial report from China. Hepatol Int. 2020;14:478-482. [PMID: 32440857 DOI: 10.1007/s12072-020-10051-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
94 Chen W, Chen X, Yang L, Wang G, Li J, Wang S, Chan Q, Xu D. Quantitative assessment of liver function with whole-liver T1rho mapping at 3.0T. Magn Reson Imaging 2018;46:75-80. [PMID: 29109053 DOI: 10.1016/j.mri.2017.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
95 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Walking Speed: Japanese Data in Chronic Liver Diseases. J Clin Med. 2020;9:166. [PMID: 31936162 DOI: 10.3390/jcm9010166] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
96 Ishizu Y, Ishigami M, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Hirooka Y, Goto H. Low skeletal muscle mass predicts early mortality in cirrhotic patients with acute variceal bleeding. Nutrition 2017;42:87-91. [DOI: 10.1016/j.nut.2017.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
97 Nishikawa H, Yoh K, Enomoto H, Iwata Y, Sakai Y, Kishino K, Shimono Y, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Koriyama T, Yuri Y, Nishimura T, Nishiguchi S, Iijima H. Serum Zinc Level Is Associated with Frailty in Chronic Liver Diseases. J Clin Med 2020;9:E1570. [PMID: 32455875 DOI: 10.3390/jcm9051570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
98 Hayashi M, Abe K, Fujita M, Okai K, Takahashi A, Ohira H. Association between sarcopenia and osteoporosis in chronic liver disease. Hepatol Res 2018;48:893-904. [PMID: 29734510 DOI: 10.1111/hepr.13192] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
99 Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and Frailty in Liver Cirrhosis. Life (Basel) 2021;11:399. [PMID: 33925660 DOI: 10.3390/life11050399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
100 Hu Z, Li W, Huang P, Zhou Z, Xu J, Xu K, Wang J, Zhang H. Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection. International Journal of Surgery 2017;48:23-31. [DOI: 10.1016/j.ijsu.2017.09.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
101 Chang Y, Liu QY, Zhang Q, Rong YM, Lu CZ, Li H. Role of nutritional status and nutritional support in outcome of hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol 2020;26:4288-301. [PMID: 32848334 DOI: 10.3748/wjg.v26.i29.4288] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
102 Uchida Y, Inao M, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis. Hepatol Res 2020;50:1355-64. [PMID: 32886950 DOI: 10.1111/hepr.13566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
103 Atsukawa M, Tsubota A, Kato K, Abe H, Shimada N, Asano T, Ikegami T, Koeda M, Okubo T, Arai T, Nakagawa-Iwashita A, Yoshida Y, Hayama K, Itokawa N, Kondo C, Chuganji Y, Matsuzaki Y, Iwakiri K. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. J Gastroenterol Hepatol 2018;33:1256-63. [PMID: 29215154 DOI: 10.1111/jgh.14047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
104 Yamada Y, Inui K, Hara Y, Fuji K, Sonoda K, Hashimoto K, Kamijo Y. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study. Sci Rep 2019;9:10195. [PMID: 31308465 DOI: 10.1038/s41598-019-46774-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
105 Bragg DA, Crowl A, Manlove E. Hepatitis C: A New Era. Prim Care 2017;44:631-42. [PMID: 29132525 DOI: 10.1016/j.pop.2017.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
106 Nishida T. Diagnosis and Clinical Implications of Diabetes in Liver Cirrhosis: A Focus on the Oral Glucose Tolerance Test. J Endocr Soc 2017;1:886-96. [PMID: 29264539 DOI: 10.1210/js.2017-00183] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
107 Nishikawa H, Shiraki M, Hiramatsu A, Hara N, Moriya K, Hino K, Koike K. Reduced handgrip strength predicts poorer survival in chronic liver diseases: A large multicenter study in Japan. Hepatol Res 2021;51:957-67. [PMID: 34057800 DOI: 10.1111/hepr.13679] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
108 Ho TW, Tsai YJ, Huang CT, Lien AS, Lai F. Impact of tobacco-related chronic obstructive pulmonary disease on developmental trajectories of comorbidities in the Taiwan population. Sci Rep 2020;10:21025. [PMID: 33273701 DOI: 10.1038/s41598-020-78325-y] [Reference Citation Analysis]
109 Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Yuri Y, Nishimura T, Iijima H, Nishiguchi S. Significant Correlation Between Grip Strength and m2bpgi in Patients with Chronic Liver Diseases. J Clin Med 2019;8:E1359. [PMID: 31480612 DOI: 10.3390/jcm8091359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
110 Suzuki Y, Naganuma A, Hoshino T, Hatanaka T, Ueno T, Namikawa M, Takizawa D, Arai H, Suzuki H, Takagi H, Tojima H, Yamazaki Y, Sato K, Kakizaki S, Uraoka T. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastroenterol Belg 2021;84:57-63. [PMID: 33639694 DOI: 10.51821/84.1.357] [Reference Citation Analysis]
111 Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-9. [PMID: 30922728 DOI: 10.1016/j.clinre.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 You H, Peng L, Zhao J, Fei Y, Wang Q, Zhang W, Li M, Zeng X. Clinical Characteristics of Systemic Lupus Erythematosus with Cirrhosis. J Immunol Res 2020;2020:2156762. [PMID: 32537465 DOI: 10.1155/2020/2156762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Yuan W, Lu HZ, Mei X, Zhang YY, Zhang ZG, Zou Y, Wang JF, Qian ZP, Guo HY. Cardiac health in patients with hepatitis B virus-related cirrhosis. Medicine (Baltimore) 2019;98:e14961. [PMID: 30921198 DOI: 10.1097/MD.0000000000014961] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
114 Cho HJ, Baek GO, Seo CW, Ahn HR, Sung S, Son JA, Kim SS, Cho SW, Jang JW, Nam SW, Cheong JY, Eun JW. Exosomal microRNA-4661-5p-based serum panel as a potential diagnostic biomarker for early-stage hepatocellular carcinoma. Cancer Med 2020;9:5459-72. [PMID: 32537885 DOI: 10.1002/cam4.3230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
115 Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K, Akahane T, Yoshiji H. Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients. World J Gastrointest Oncol 2019;11:887-97. [PMID: 31662827 DOI: 10.4251/wjgo.v11.i10.887] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Shin HW, Park HK. Recent Updates on Acquired Hepatocerebral Degeneration. Tremor Other Hyperkinet Mov (N Y) 2017;7:463. [PMID: 28975044 DOI: 10.7916/D8TB1K44] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
117 Sakaida I, Terai S, Kurosaki M, Yasuda M, Okada M, Bando K, Fukuta Y. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study): Effectiveness, safety of tolvaptan in cirrhosis. Hepatol Res 2017;47:1137-46. [DOI: 10.1111/hepr.12852] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
118 Chai Y, Li K, Zhang C, Chen S, Ma K. The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma. BMC Cancer 2019;19:497. [PMID: 31133001 DOI: 10.1186/s12885-019-5707-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Zhu ZR, Liu WL, Ding ZM, Li Y. Efficacy of furosemide for treatment of liver cirrhosis: A systematic review protocol of randomized controlled trial. Medicine (Baltimore) 2019;98:e15300. [PMID: 31008980 DOI: 10.1097/MD.0000000000015300] [Reference Citation Analysis]
120 Fan K, Wu K, Lin L, Ge P, Dai J, He X, Hu K, Zhang L. Metformin mitigates carbon tetrachloride-induced TGF-β1/Smad3 signaling and liver fibrosis in mice. Biomedicine & Pharmacotherapy 2017;90:421-6. [DOI: 10.1016/j.biopha.2017.03.079] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
121 Cho HJ, Baek GO, Yoon MG, Ahn HR, Son JA, Kim SS, Cheong JY, Eun JW. Overexpressed Proteins in HCC Cell-Derived Exosomes, CCT8, and Cofilin-1 Are Potential Biomarkers for Patients with HCC. Diagnostics (Basel) 2021;11:1221. [PMID: 34359304 DOI: 10.3390/diagnostics11071221] [Reference Citation Analysis]
122 Kawaratani H, Fukui H, Yoshiji H. Treatment for cirrhotic ascites. Hepatol Res. 2017;47:166-177. [PMID: 27363974 DOI: 10.1111/hepr.12769] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
123 Arase Y, Kagawa T, Tsuruya K, Sato H, Teramura E, Anzai K, Hirose S, Deguchi R, Shiraishi K, Mine T. Impaired Renal Function May Not Negate the Efficacy of Tolvaptan in the Treatment of Cirrhotic Patients with Refractory Ascites. Clin Drug Investig 2019;39:45-54. [PMID: 30284699 DOI: 10.1007/s40261-018-0714-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
124 Lee KS, Santagostino SF, Li D, Ramjit A, Serrano K, Ginsberg MD, Ding BS, Rafii S, Madoff DC. Catheter-directed Intraportal Delivery of Endothelial Cell Therapy for Liver Regeneration: A Feasibility Study in a Large-Animal Model of Cirrhosis. Radiology 2017;285:114-23. [PMID: 28498793 DOI: 10.1148/radiol.2017162617] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
125 Kogiso T, Tokushige K. Fontan-associated liver disease and hepatocellular carcinoma in adults. Sci Rep 2020;10:21742. [PMID: 33303924 DOI: 10.1038/s41598-020-78840-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
126 Miyamoto Y, Enomoto H, Nishikawa H, Nishimura T, Iwata Y, Nishiguchi S, Iijima H. Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices. In Vivo 2021;35:1163-8. [PMID: 33622916 DOI: 10.21873/invivo.12364] [Reference Citation Analysis]
127 Hoshino Y, Sugihara T, Ikeda S, Matsuki Y, Nagahara T, Okano JI, Isomoto H. A vein-viewing application enabled detecting abdominal wall varices related to the presence of non-treated gastroesophageal varices: a cross-sectional study. BMC Med Imaging 2021;21:120. [PMID: 34372801 DOI: 10.1186/s12880-021-00655-8] [Reference Citation Analysis]
128 Hu Z, Huang P, Zhou Z, Li W, Xu J, Xu K, Wang J, Zhang H. Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis. Clin Transl Oncol 2018;20:729-39. [DOI: 10.1007/s12094-017-1779-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
129 Fukui H. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. J Clin Transl Hepatol 2017;5:249-60. [PMID: 28936406 DOI: 10.14218/JCTH.2017.00008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
130 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Reference Citation Analysis]
131 Nishikawa H, Yoh K, Enomoto H, Nishimura T, Nishiguchi S, Iijima H. Combined grip strength and calf circumference as a useful prognostic system in patients with liver diseases: a large cohort study. Ann Transl Med 2021;9:624. [PMID: 33987322 DOI: 10.21037/atm-20-6901] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore) 2019;98:e15297. [PMID: 31027094 DOI: 10.1097/MD.0000000000015297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
133 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Reference Citation Analysis]
134 Ren Y, Liu L, Li Y, Yang F, He Y, Zhu Y, Hu X, Lin S. Development and validation of a scoring system to predict progression to acute-on-chronic liver failure in patients with acute exacerbation of chronic hepatitis B. Hepatol Res. 2018;48:692-700. [PMID: 29336092 DOI: 10.1111/hepr.13062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
135 Xu WP, Wang ZR, Zou X, Zhao C, Wang R, Shi PM, Yuan ZL, Yang F, Zeng X, Wang PQ, Sultan S, Zhang Y, Xie WF. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein evaluates liver function and predicts prognosis in liver cirrhosis. J Dig Dis. 2018;19:242-253. [PMID: 29607614 DOI: 10.1111/1751-2980.12596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
136 Wang T, Shen J. Usefulness of Simplified Nutritional Appetite Questionnaire (SNAQ) in Appetite Assessment in Elder Patients with Liver Cirrhosis. J Nutr Health Aging 2018;22:911-5. [DOI: 10.1007/s12603-018-1086-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
137 Suzuki K, Endo R, Takikawa Y, Moriyasu F, Aoyagi Y, Moriwaki H, Terai S, Sakaida I, Sakai Y, Nishiguchi S, Ishikawa T, Takagi H, Naganuma A, Genda T, Ichida T, Takaguchi K, Miyazawa K, Okita K. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial. Hepatol Res. 2018;48:411-423. [PMID: 29235218 DOI: 10.1111/hepr.13045] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
138 Yuri Y, Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Nishimura T, Iijima H, Nishiguchi S. Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis. J Clin Med 2019;9:E95. [PMID: 31905953 DOI: 10.3390/jcm9010095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
139 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]